10 results

  • mounjaro

    (tirzepatide)
    Eli Lilly and Company
    MOUNJARO® is indicated as an adjunct to diet and exercise to enhance glycemic control in adults with type 2 diabetes mellitus. It is not studied in patients with pancreatitis and is not indicated for type 1 diabetes mellitus.

  • ozempic

    (semaglutide)
    Novo Nordisk
    OZEMPIC is indicated as an adjunct to diet and exercise for improving glycemic control in adults with type 2 diabetes mellitus, reducing the risk of major cardiovascular events in those with cardiovascular disease, and minimizing the risk of kidney disease progression in patients with chronic kidney disease.

  • rybelsus

    (Oral Semaglutide)
    Novo Nordisk
    RYBELSUS is indicated for improving glycemic control in adults with type 2 diabetes mellitus, used alongside diet and exercise. It is not recommended for patients with type 1 diabetes mellitus.

  • saxenda

    (liraglutide)
    Novo Nordisk
    SAXENDA is indicated for weight management in adults and patients aged 12 and older with obesity (≥60 kg) or with overweight plus a weight-related comorbidity, alongside a reduced-calorie diet and increased physical activity. Coadministration with other liraglutide-containing products is not recommended.

  • soliqua 100/33

    (insulin glargine and lixisenatide)
    sanofi-aventis U.S. LLC
    SOLIQUA 100/33 is indicated to improve glycemic control in adults with type 2 diabetes mellitus as an adjunct to diet and exercise. It is not recommended for patients with a history of pancreatitis or gastroparesis, or for use in type 1 diabetes or with other GLP-1 receptor agonists.

  • trulicity

    (Dulaglutide)
    Eli Lilly and Company
    TRULICITY® is indicated for improving glycemic control in adults and pediatric patients (10 years and older) with type 2 diabetes mellitus, and for reducing major cardiovascular event risks in adults with the same condition who have cardiovascular disease or risk factors. Limitations include its unsuitability for type 1 diabetes and certain gastrointestinal conditions.

  • victoza

    (liraglutide)
    Novo Nordisk
    VICTOZA is indicated to improve glycemic control in adults and pediatric patients (10+) with type 2 diabetes mellitus, and to reduce the risk of major cardiovascular events in adults with type 2 diabetes and established cardiovascular disease. Not for use in type 1 diabetes patients or with other liraglutide products.

  • wegovy

    (semaglutide)
    Novo Nordisk
    WEGOVY is indicated for use alongside a reduced-calorie diet and increased physical activity to reduce cardiovascular event risks in adults with cardiovascular disease and obesity or overweight, and to aid in weight reduction for adults and pediatric patients aged 12 and older with obesity or related comorbid conditions.

  • xultophy 100/3.6

    (insulin degludec and liraglutide)
    Novo Nordisk
    XULTOPHY 100/3.6 is indicated as an adjunct to diet and exercise for improving glycemic control in adults with type 2 diabetes mellitus. It is not recommended as first-line therapy, nor for use with liraglutide-containing products, and is not for type 1 diabetes or diabetic ketoacidosis.

  • zepbound

    (tirzepatide)
    Eli Lilly and Company
    ZEPBOUND® is indicated for weight reduction and long-term maintenance in adults with obesity or overweight and related comorbid conditions, as well as for treating moderate to severe obstructive sleep apnea in adults with obesity. Co-administration with other tirzepatide products or GLP-1 receptor agonists is not recommended.